In a report released yesterday, Stan Berenshteyn from Wells Fargo reiterated a Buy rating on GoodRx Holdings, with a price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stan Berenshteyn has given his Buy rating due to a combination of factors that suggest a positive outlook for GoodRx Holdings. Despite near-term growth challenges from store closures and lower ISP volumes, the company is positioned for significant growth in 2026 with several catalysts. These include a brand relaunch, new partnerships with pharmacy benefit managers, and expansion in cash pay total addressable market.
Additionally, the company’s Pharma Manufacturing Solutions, ‘ManSol,’ has shown impressive growth, and the anticipated launch of new direct-to-consumer subscriptions could further enhance revenue. While the 2025 guidance has been adjusted downward, the company’s ability to defend its margins and the potential for increased marketing spend to support new product launches provide a strong foundation for future growth. These strategic initiatives and the potential rise in uninsured individuals present opportunities for GoodRx to capitalize on market expansion, justifying the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $8.00 price target.
GDRX’s price has also changed moderately for the past six months – from $4.840 to $3.470, which is a -28.31% drop .